News at Heart Metabolics

Press Release

Heart Metabolics Annouces Initiation of Phase 2b Study of Perhexiline for Hypertrophic Cardiomyopathy

Dublin, Ireland and San Francisco – August 31, 2016 — Heart Metabolics Limited (Heart Metabolics), a biotechnology company focused on the development of drugs for orphan diseases including hypertrophic cardiomyopathy (HCM), today announced it has initiated dosing in patients for an open-label Phase 2b study of perhexiline in patients with HCM and moderate-to-severe heart failure with …

Press Release

Heart Metabolics Adds New Board Member and Expands Senior Management Team

Board and clinical development team strengthened Dublin, Ireland and San Francisco – May 17, 2016 — Heart Metabolics Limited (Heart Metabolics), a biotechnology company focused on the development of drugs for orphan diseases including hypertrophic cardiomyopathy (HCM), today announced the appointment of Sean Gallagher to the board of directors and the addition of Charlotte Hartman, Pharm.D., …

Press Release

Heart Metabolics Announces Multiple Senior Appointments to Management Team

All Functional Areas Strengthened to Support Advancement of the Clinical Pipeline Dublin, Ireland—March 15, 2016: Heart Metabolics Limited (Heart Metabolics), a biotechnology company focused on the development of drugs for orphan diseases including hypertrophic cardiomyopathy (HCM), today announced three key additions to the executive team – Dr. Robert Shalwitz as Chief Operating Officer, Dr. Mark …

Press Release

Heart Metabolics and FDA Reach Agreement on Special Protocol Assessment for Single Phase 3 Trial of Perhexiline in Hypertrophic Cardiomyopathy

Company Appoints William Daly as Chief Executive Officer and Gregory M. Ayers, M.D., Ph.D., as Chief Medical Officer Dublin, Ireland—April 15, 2015: Heart Metabolics Limited, a biotechnology company focused on the development of drugs for orphan diseases including hypertrophic cardiomyopathy (HCM), today announced that it has received an agreement letter from the U.S. Food and …

Media

With $20 million, old drug offers new look at rare heart condition

San Francisco Business Times
Press Release

Heart Metabolics Limited Launched in Ireland with $20 Million Series A Financing

Dublin, Ireland— April 17, 2014: Heart Metabolics Limited, a new Irish biotechnology company focused on development of drugs for cardio-metabolic diseases including the treatment of hypertrophic cardiomyopathy (“HCM”), has announced the completion of a $20 million Series A financing from venBio, Seroba Kernel Life Sciences, Brandon Capital Partners (on behalf of AustralianSuper) and AshHill. The …